MXPA04012150A - Sistema terapeutico transdermico para administrar rotigotina. - Google Patents

Sistema terapeutico transdermico para administrar rotigotina.

Info

Publication number
MXPA04012150A
MXPA04012150A MXPA04012150A MXPA04012150A MXPA04012150A MX PA04012150 A MXPA04012150 A MX PA04012150A MX PA04012150 A MXPA04012150 A MX PA04012150A MX PA04012150 A MXPA04012150 A MX PA04012150A MX PA04012150 A MXPA04012150 A MX PA04012150A
Authority
MX
Mexico
Prior art keywords
hot melt
rotigotine
tts
melt tts
adhesive layer
Prior art date
Application number
MXPA04012150A
Other languages
English (en)
Inventor
Breitenbach Armin
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of MXPA04012150A publication Critical patent/MXPA04012150A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion se refiere a un sistema terapeutico transdermico (TTS) que contiene una capa adhesiva que contiene rotigotina, y que se caracteriza por el hecho de que la capa adhesiva contiene un adhesivo de contacto que puede fundir con calor. La invencion se refiere tambien al uso de rotigotina para producir la capa adhesiva de un TTS en un metodo de fusion con calor; y a un metodo para producir dicho TTS.
MXPA04012150A 2002-07-30 2003-07-29 Sistema terapeutico transdermico para administrar rotigotina. MXPA04012150A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10234673A DE10234673B4 (de) 2002-07-30 2002-07-30 Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
PCT/EP2003/008348 WO2004012721A2 (de) 2002-07-30 2003-07-29 Heissschmelz-tts zur verabreichungvon rotigotin

Publications (1)

Publication Number Publication Date
MXPA04012150A true MXPA04012150A (es) 2005-09-21

Family

ID=30469194

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04012150A MXPA04012150A (es) 2002-07-30 2003-07-29 Sistema terapeutico transdermico para administrar rotigotina.

Country Status (22)

Country Link
US (1) US9186335B2 (es)
EP (2) EP1669063A1 (es)
JP (1) JP4514608B2 (es)
KR (1) KR101041512B1 (es)
CN (1) CN100574755C (es)
AT (1) ATE324875T1 (es)
AU (1) AU2003269859B2 (es)
BR (1) BR0311437A (es)
CA (1) CA2494361C (es)
CY (1) CY1105138T1 (es)
DE (2) DE10234673B4 (es)
DK (1) DK1492517T3 (es)
ES (1) ES2263999T3 (es)
HK (1) HK1081436A1 (es)
IL (1) IL166070A0 (es)
MX (1) MXPA04012150A (es)
NO (1) NO20050835L (es)
PL (1) PL221308B1 (es)
PT (1) PT1492517E (es)
RU (1) RU2304434C2 (es)
WO (1) WO2004012721A2 (es)
ZA (1) ZA200500457B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
DE10234673B4 (de) 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246979B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
JP4986411B2 (ja) * 2004-06-01 2012-07-25 久光製薬株式会社 貼付剤
US8173155B2 (en) * 2004-06-01 2012-05-08 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
JP2008514376A (ja) * 2004-09-29 2008-05-08 シュウォーツ ファーマ インコーポレイテッド パーキンソン病のための経皮治療システム
DE102006026578B4 (de) 2006-06-08 2009-01-08 Lts Lohmann Therapie-Systeme Ag Wirkstoffpartikelhaltiges Transdermales Therapeutisches System mit erhöhtem Wirkstofffluss und Verfahren zu seiner Herstellung sowie Verwendung
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途
DE102006059462A1 (de) * 2006-12-14 2008-06-19 Henkel Kgaa Hot melt für Mikrowellen-Erwärmung
US20080226698A1 (en) * 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
US8344165B2 (en) 2007-05-30 2013-01-01 Chemagis Ltd. Crystalline rotigotine base and preparation process therefor
CN101147739B (zh) * 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
EP2215072B1 (en) * 2007-11-28 2015-09-02 UCB Pharma GmbH Polymorphic form of rotigotine
AU2009302853B2 (en) * 2008-10-06 2014-09-11 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
DE102009052972A1 (de) 2009-11-12 2011-09-15 Lts Lohmann Therapie-Systeme Ag Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm
EP3257504B1 (en) * 2009-12-22 2024-06-19 UCB Biopharma SRL Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
MX339408B (es) * 2010-03-09 2016-05-24 Alkermes Pharma Ireland Ltd Composiciones farmaceuticas entericas resistentes al alcohol.
WO2012068783A1 (en) * 2010-11-25 2012-05-31 Shan Dong Luye Pharmaceutical Co., Ltd. Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
WO2012084969A1 (en) 2010-12-22 2012-06-28 Hexal Ag Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
JP5856424B2 (ja) * 2011-10-05 2016-02-09 祐徳薬品工業株式会社 ロチゴチン含有経皮吸収型貼付剤
WO2013075822A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system (tts) with rotigotine
DE102012013439A1 (de) 2012-07-03 2014-01-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
DE102011119043A1 (de) 2011-11-22 2013-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TDS) mit Rotigotin
DE102011090178A1 (de) * 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
WO2014007579A1 (ko) * 2012-07-05 2014-01-09 에스케이케미칼(주) 로티고틴을 함유한 경피흡수제제
JP2015522013A (ja) * 2012-07-06 2015-08-03 エスケー ケミカルス カンパニー リミテッド ロチゴチン含有経皮吸収製剤
TW201431570A (zh) * 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片
WO2014193190A1 (ko) * 2013-05-30 2014-12-04 에스케이케미칼 (주) 로티고틴과 지방산 및 스티렌 점착제를 함유한 경피치료시스템
US20160199316A1 (en) * 2013-06-14 2016-07-14 Tesa Labtec Gmbh Three-layer transdermal therapy system (tts)
WO2014198422A1 (de) * 2013-06-14 2014-12-18 Tesa Labtec Gmbh Transdermales therapiesystem (tts) mit rotigotin
WO2014205325A2 (en) * 2013-06-20 2014-12-24 Mylan Technologies, Inc. Storage stable transdermal patch of rotigotine
BR112015032929B1 (pt) 2013-07-03 2022-08-23 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico com componente eletrônico e métodos de produção de um sistema terapêutico transdérmico
CN106456568B (zh) 2014-05-20 2020-03-27 Lts勒曼治疗系统股份公司 包含界面调节剂的经皮递送系统
JP6573913B2 (ja) 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
JP6895755B2 (ja) * 2014-05-20 2021-06-30 エルテーエス ローマン テラピー−ジステーメ アーゲー 経皮送達システムにおける活性薬剤の放出を調節するための方法
KR102364378B1 (ko) * 2014-05-21 2022-02-16 에스케이케미칼 주식회사 안정성을 향상시킨 로티고틴 함유 경피흡수제제
WO2019234662A1 (en) * 2018-06-07 2019-12-12 Nal Pharmaceutical Group Limited Transdermal drug delivery system containing rotigotine
KR20200046461A (ko) * 2018-10-24 2020-05-07 에스케이케미칼 주식회사 비결정 로티고틴 함유 조성물 및 이의 제조 방법
KR102260202B1 (ko) * 2019-10-30 2021-06-03 에바바이오 주식회사 로티고틴 공융 혼합물 및 이의 용도
FI3854388T3 (fi) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermaalinen hoitojärjestelmä, jossa on vaikuttava aine rotigotiini ja ainakin yksi ei-amiiniresistentti silikoniliima

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36754A (en) * 1862-10-21 Improvement in watch-chain guards or keys
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US5177112A (en) 1983-01-03 1993-01-05 Whitby Research, Inc. Substituted 2-aminotetralins
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US4880633A (en) 1986-03-12 1989-11-14 Merck & Co., Inc. Transdermal drug delivery system
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
DE3743945A1 (de) * 1987-09-01 1989-03-09 Lohmann Gmbh & Co Kg Vorrichtung zur abgabe von stoffen, verfahren zu ihrer herstellung sowie ihre verwendung
US5273757A (en) 1987-09-01 1993-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Apparatus for the delivery of substances, processes for the production thereof and use thereof
US4915950A (en) 1988-02-12 1990-04-10 Cygnus Research Corporation Printed transdermal drug delivery device
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
DE3827561C1 (es) 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US4865920A (en) 1988-09-20 1989-09-12 Dow Corning Corporation Hot-melt pressure sensitive adhesive article and method of making
US4973468A (en) 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
FR2648131B1 (fr) 1989-06-13 1991-10-18 Oreal Nouveaux derives de tetrahydro -5,6,7,8 naphtalenol-1, leur procede de preparation et leur utilisation en tant qu'agents antioxydants dans des compositions cosmetiques et pharmaceutiques les contenant
US5252335A (en) 1989-07-12 1993-10-12 Cygnus Therapeutic Systems Transdermal administration of lisuride
US5091186A (en) 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US5271940A (en) 1989-09-14 1993-12-21 Cygnus Therapeutic Systems Transdermal delivery device having delayed onset
DE3933460A1 (de) 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts Oestrogenhaltiges wirkstoffpflaster
US5246997A (en) * 1990-02-21 1993-09-21 Dow Corning Corporation Method of making a hot-melt silicone pressure sensitive adhesive-coated substrate
US5147916A (en) * 1990-02-21 1992-09-15 Dow Corning Corporation Hot-melt silicone pressure sensitive adhesive composition and related methods and articles
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5300299A (en) * 1991-07-22 1994-04-05 Dow Corning Corporation Silicone pressure sensitive adhesive containing alkylmethylsiloxane wax and related methods and devices
US5328696A (en) * 1991-07-22 1994-07-12 Dow Corning Corporation Devices using silicone pressure sensitive adhesives containing organic wax
US5273756A (en) 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset
US5234690A (en) 1991-08-23 1993-08-10 Cygnus Therapeutic Systems Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset
US5273755A (en) 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset
US5225198A (en) 1991-08-27 1993-07-06 Cygnus Therapeutic Systems Transdermal administration of short or intermediate half-life benzodiazepines
WO1993003697A1 (en) 1991-08-27 1993-03-04 Cygnus Therapeutic Systems Transdermal formulations for administering prazosin
JPH05208907A (ja) 1991-09-17 1993-08-20 Sekisui Chem Co Ltd 消炎鎮痛貼付剤
AU2782592A (en) 1991-10-15 1993-05-21 Cygnus Therapeutic Systems Thermal enhancement of transdermal drug administration
WO1993014727A1 (en) 1992-01-31 1993-08-05 Cygnus Therapeutic Systems Transdermal administration of buprenorphine in the form of ion pair complexes
GB9202915D0 (en) 1992-02-12 1992-03-25 Wellcome Found Chemical compounds
DE4224325C1 (de) 1992-07-23 1994-02-10 Sanol Arznei Schwarz Gmbh Wirkstoffpflaster für niedrigschmelzende und/oder flüchtige Wirkstoffe und Verfahren zu seiner Herstellung
AU3247193A (en) 1992-08-25 1994-03-15 Cygnus Therapeutic Systems Printed transdermal drug delivery device
US5308625A (en) 1992-09-02 1994-05-03 Cygnus Therapeutic Systems Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
US5989586A (en) 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
DE4301781C2 (de) * 1993-01-23 1995-07-20 Lohmann Therapie Syst Lts Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
EP0711153A1 (en) 1993-06-24 1996-05-15 Cygnus, Inc. Transdermal delivery system package
WO1995001767A1 (en) 1993-07-08 1995-01-19 Cygnus Therapeutic Systems Monolithic matrix transdermal delivery system
US5382596A (en) 1993-08-05 1995-01-17 Whitby Research, Inc. Substituted 2-aminotetralins
US5554381A (en) 1993-08-09 1996-09-10 Cygnus, Inc. Low flux matrix system for delivering potent drugs transdermally
WO1995005137A1 (en) 1993-08-16 1995-02-23 Cygnus Therapeutic Systems Transdermal delivery system using a combination of permeation enhancers
AU7566994A (en) 1993-08-16 1995-03-14 Cygnus Therapeutic Systems Contact adhesive extends wear time on skin
US5482988A (en) * 1994-01-14 1996-01-09 Dow Corning Corporation Hot-melt silicone pressure sensitive adhesive with siloxylated polyether waxes as additives
KR100329876B1 (ko) 1994-03-11 2002-08-13 코닌클리케 필립스 일렉트로닉스 엔.브이. 의사주기신호용전송시스템
AU2944995A (en) 1994-06-24 1996-01-19 Cygnus, Inc. Iontophoretic sampling device and method
US5771890A (en) 1994-06-24 1998-06-30 Cygnus, Inc. Device and method for sampling of substances using alternating polarity
US6024974A (en) 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
WO1996022083A1 (en) 1995-01-19 1996-07-25 Cygnus, Inc. POLYISOBUTYLENE ADHESIVES CONTAINING HIGH Tg TACKIFIER FOR TRANSDERMAL DEVICES
WO1996022084A2 (en) 1995-01-19 1996-07-25 Cygnus, Inc. Polymer adhesive formulation containing sorbent particles
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
GB9511366D0 (en) 1995-06-06 1995-08-02 Smithkline Beecham Plc Novel formulations
AU6032696A (en) 1995-06-07 1996-12-30 Cygnus Therapeutic Systems Pressure sensitive acrylate adhesive composition cross-linke d with aluminum acetylacetonate and containing a drug having a reactive aromatic hydroxyl group
US5785991A (en) 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
UA48973C2 (uk) 1995-06-07 2002-09-16 Орто-Макнейл Фармасьютікалз Інк. Трансдермальний пластир на основі 17-деацетилноргестимату для попередження овуляції
US5559165A (en) 1995-08-08 1996-09-24 National Starch And Chemical Investment Holding Corporation Hot melt adhesives for bonding to sensitive areas of the human body
US5906830A (en) 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5902603A (en) 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
WO1997009971A2 (en) 1995-09-14 1997-03-20 Cygnus, Inc. High capacity, superabsorbent drug reservoirs for use in transdermal drug delivery systems
US5891461A (en) 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
US6063398A (en) 1995-09-20 2000-05-16 L'oreal Cosmetic or dermopharmaceutical patch containing, in an anhydrous polymeric matrix, at least one active compound which is, in particular, unstable in oxidizing mediums, and at least one water-absorbing agent
US5807570A (en) 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
US5733571A (en) 1995-12-08 1998-03-31 Euro-Celtique, S.A. Transdermal patch for comparative evaluations
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5843472A (en) 1997-02-28 1998-12-01 Cygnus, Inc. Transdermal drug delivery sytem for the administration of tamsulosin, and related compositions and methods of use
US5879701A (en) 1997-02-28 1999-03-09 Cygnus, Inc. Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
CA2329411C (en) 1998-05-13 2004-01-27 Cygnus, Inc. Collection assemblies for transdermal sampling system
DE19821788C1 (de) 1998-05-15 1999-12-02 Sanol Arznei Schwarz Gmbh Transdermales Therapeutisches System (TTS) Pergolid enthaltend
DE19828273B4 (de) 1998-06-25 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren
DE69913153D1 (de) 1998-09-17 2004-01-08 Cygnus Therapeutic Systems Gerät zum zusammendrücken einer gel/sensor-einheit
ES2244422T3 (es) 1999-04-01 2005-12-16 Alza Corporation Dispositivos para la administracion transdermica de farmacos que comprenden un deposito de poliuretano para farmacos.
FR2792529B1 (fr) 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
AU5325000A (en) 1999-06-05 2000-12-28 David Houze Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use
US6218421B1 (en) 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
DE19958554C2 (de) * 1999-07-02 2002-06-13 Lohmann Therapie Syst Lts Mikroreservoirsystem auf Basis von Polysiloxanen und ambiphilen Lösemitteln und ihre Herstellung
DE19940238A1 (de) 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten
DE60008136T2 (de) 1999-11-23 2004-09-09 Aderis Pharmaceuticals, Inc. Verbessertes verfahren zur herstellung von n-substituierte aminotetraline
JP5753645B2 (ja) 1999-11-29 2015-07-22 エルテーエス ローマン テラピー−ジステーメ アーゲー 安定性が改善された経皮治療システムおよびそれらの製法
US20020110585A1 (en) 1999-11-30 2002-08-15 Godbey Kristin J. Patch therapeutic agent delivery device having texturized backing
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20020119187A1 (en) 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
US20030027793A1 (en) 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20030026830A1 (en) 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
ES2203563T3 (es) 2001-05-08 2004-04-16 Schwarz Pharma Ag Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson.
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
US20060263419A1 (en) 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
CA2481934A1 (en) 2002-04-18 2003-10-30 Pharmacia Corporation Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
US20040048779A1 (en) 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US20060216336A1 (en) 2002-05-07 2006-09-28 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
KR20050045946A (ko) * 2002-06-25 2005-05-17 애크럭스 디디에스 피티와이 리미티드 비정질 약학적 조성물을 이용한 경피전달속도의 제어
DE10234673B4 (de) 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246980B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8211462B2 (en) 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
PT1426049E (pt) 2002-12-02 2005-09-30 Sanol Arznei Schwarz Gmbh Administracao iontoforetica de rotigotina para o tratamento da doenca de parkinson
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
TWI392670B (zh) 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
EP2215072B1 (en) 2007-11-28 2015-09-02 UCB Pharma GmbH Polymorphic form of rotigotine
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
EP3257504B1 (en) 2009-12-22 2024-06-19 UCB Biopharma SRL Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine

Also Published As

Publication number Publication date
US20050260254A1 (en) 2005-11-24
CY1105138T1 (el) 2009-11-04
CA2494361A1 (en) 2004-02-12
EP1492517A2 (de) 2005-01-05
DE10234673A1 (de) 2004-02-19
WO2004012721A2 (de) 2004-02-12
KR101041512B1 (ko) 2011-06-16
WO2004012721A3 (de) 2004-04-08
ES2263999T3 (es) 2006-12-16
RU2005105684A (ru) 2005-11-20
NO20050835L (no) 2005-02-16
PL374852A1 (en) 2005-11-14
CN100574755C (zh) 2009-12-30
AU2003269859A1 (en) 2004-02-23
DE50303201D1 (de) 2006-06-08
US9186335B2 (en) 2015-11-17
ATE324875T1 (de) 2006-06-15
CA2494361C (en) 2010-11-02
EP1492517B1 (de) 2006-05-03
JP2006508908A (ja) 2006-03-16
IL166070A0 (en) 2006-01-15
DK1492517T3 (da) 2006-08-28
KR20050038007A (ko) 2005-04-25
PL221308B1 (pl) 2016-03-31
EP1669063A1 (de) 2006-06-14
CN1671364A (zh) 2005-09-21
DE10234673B4 (de) 2007-08-16
JP4514608B2 (ja) 2010-07-28
HK1081436A1 (en) 2006-05-19
BR0311437A (pt) 2005-03-22
PT1492517E (pt) 2006-09-29
RU2304434C2 (ru) 2007-08-20
ZA200500457B (en) 2005-08-31
AU2003269859B2 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
MXPA04012150A (es) Sistema terapeutico transdermico para administrar rotigotina.
ZA200706885B (en) Non fibrous transdermal therapeutic system and method for its production
MXPA06007171A (es) Derivados de ciclohexano espirociclicos con afinidad para el receptor orl1.
TWI345978B (en) Combination therapy comprising glucose reabsorption inhibitors and retinoid x receptor modulators
HK1082199A1 (en) Transdermal granisetron
PH12013500772A1 (en) Transdermal therapeutic system
AU2003267203A8 (en) Method for administering thermotherapy to prevent the growth of tumors
RS91004A (en) Methods of treating ileus
MX2008008413A (es) Composicion farmaceutica para el tratamiento de las enfermedades de las uñas.
DK0973544T3 (da) Immuntolerant prothrombinkomplekspræparat
WO2002096351A3 (en) Ultrashort-acting opioids for transdermal application
TW200740425A (en) Production method of nicotine transdermal preparation
IL176032A0 (en) Percutaneous absorption-type pharmaceutical preparation
HUP0204448A2 (en) Trnasdermal therapeutic system for the delivery of lerisetron
PL372313A1 (en) Method for producing pseudo islets
MY127328A (en) 5-amino-1-pentene-3-ol substituted derivatives
WO2005019169A3 (de) Indolin-derivate als ppar delta modulatoren
TW200621266A (en) Methods of treating proliferative skin diseases using carbazole derivatives
SE0101257D0 (sv) Treatment of whiplash associated disorder
UA87292C2 (ru) Применение сирамезина для лечения злокачественных опухолей
ITMI20022594A1 (it) Combinazione terapeutica per la cura dell'ipertensione.
UA2972U (uk) Спосіб лікування початкових проявів розсіяного склерозу
SI1492517T1 (sl) TTS z vroco talino za dajanje rotigotina

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: SCHOTT GLAS